Skip to main content
SpringerLink
Log in

Complications of the Medications

  • Chapter
Complications of Percutaneous Coronary Interventions

  • 798 Accesses

Abstract

In the United States nearly 600,000 percutaneous coronary interventions (PCI) are performed annually.1 Adjunctive pharmacologic therapies are used to facilitate and assure favorable patient outcomes in the setting of PCI.2–4 However, complications, some severe, occur with the use of these adjunctive therapies. This chapter will discuss selected complications, including their prevention and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Heart Association. Heart disease and stroke statistics—2004 update. Dallas, TX: American Heart Association; 2003.

    Google Scholar 

  2. Braunwald E, Antman EM, Beasley JW, et al. Management of patients with unstable angina and non-ST-segment elevation myocardial infarction update. J Am Coll Cardiol. 2002;40:1366–1374.

    Article  PubMed  Google Scholar 

  3. Philipp R, Grech ED. ABC of interventional cardiology. Interventional pharmacotherapy. Br Med J. 2003;327:43–46.

    Article  CAS  Google Scholar 

  4. Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation. 2003;108(suppl III);III–22–III–27.

    Google Scholar 

  5. Moscucci M. Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents. J Invasive Cardiol. 2002;14(suppl B):55B–64B.

    PubMed  Google Scholar 

  6. Lopez LM. Clinical challenges of bleeding in percutaneous coronary intervention. Am J Health Syst Pharm. 2003;60(suppl 3):S8–S14.

    PubMed  Google Scholar 

  7. Dauerman HL, Andreou C, Perras MA, et al. Predictors of bleeding complications after rescue coronary interventions. J Thromb Thrombolysis. 2000;10:83–88.

    Article  CAS  PubMed  Google Scholar 

  8. Rammohan C, Fintel D. Dosing considerations and monitoring of low molecular weight heparin and glycoprotein IIb/IIIa antagonists in patients with renal insufficiency. Curr Cardiol Rep. 2003;5:303–309.

    Article  PubMed  Google Scholar 

  9. Reddan D, Szczech LA, O’Shea S, et al. Anticoagulation in acute cardiac care in patients with chronic kidney disease. Am Heart J. 2003;145:586–594.

    Article  PubMed  Google Scholar 

  10. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother. 2004;38:25–29.

    Article  CAS  PubMed  Google Scholar 

  11. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 1992;22:359–374.

    Article  CAS  PubMed  Google Scholar 

  12. Pichette V, Leblond FA. Drug metabolism in chronic renal failure. Curr Drug Metab. 2003;4:91–103.

    Article  CAS  PubMed  Google Scholar 

  13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;6:31–41.

    Article  Google Scholar 

  14. Goral S, Ynares C, Shyr Y, et al. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J Heart Lung Transplant. 1997;16:1106–1112.

    CAS  PubMed  Google Scholar 

  15. Kalra S, Bell MR, Rihal CS. Alveolar hemorrhage as a complication of treatment with abciximab. Chest. 2001;120:126–131.

    Article  CAS  PubMed  Google Scholar 

  16. Khanlou H, Tsiodras S, Eiger G, et al. Fatal alveolar hemorrhage and abciximab (ReoPro) therapy for acute myocardial infarction. Catheter Cardiovasc Intervent. 1998;44:313–316.

    CAS  Google Scholar 

  17. Ali A, Paul S, Grady KJ, et al. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: anemesis of platelet glycoprotein IIb/IIIa inhibitors. Catheter Cardiovasc Intervent. 2000;49:181–184.

    Article  CAS  Google Scholar 

  18. Ali A, Hashem M, Rosman HS, et al. Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage. J Invasive Cardiol. 2003;15:186–188.

    PubMed  Google Scholar 

  19. Orford JL, Fasseas P, Holmes DR, et al. Alveolar hemorrhage associated with periprocedural eptifibatide. J Invasive Cardiol. 2004;16:341–342.

    PubMed  Google Scholar 

  20. Kilaru PK, Schweigher MJ, Kozman HA, et al. Diffuse alveolar hemorrhage after Clopidogrel use. J Invasive Cardiol. 2001;13:535–537.

    CAS  PubMed  Google Scholar 

  21. Awadh N, Ronco JJ, Bernstein V, et al. Spontaneous pulmonary hemorrhage after thrombolytic therapy for acute myocardial infarction. Chest. 1994;106:1622–1624.

    Article  CAS  PubMed  Google Scholar 

  22. Gaspari F, Vigano G, Orisio S, et al. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest. 1987;79:1788–1797.

    Article  CAS  PubMed  Google Scholar 

  23. Dai H, Chen J, Tao Q, et al. Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty. Postgrad Med J. 2003;79:522–526.

    Article  CAS  PubMed  Google Scholar 

  24. Mukherjee D, Chew DP, Robbins M, et al. Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. J Thromb Thrombolysis. 2001;11:151–154.

    Article  CAS  PubMed  Google Scholar 

  25. Lineoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA. 2003;289:853–863.

    Article  Google Scholar 

  26. Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: a metaanalysis of randomized trials. Am J Cardiol. 2003;92:919–923.

    Article  CAS  PubMed  Google Scholar 

  27. Gupta V, Aravamuthan BR, Baskerville S, et al. Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, “real world” registry. J Invasive Cardiol. 2004;16:304–310.

    PubMed  Google Scholar 

  28. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555–1562.

    Article  CAS  PubMed  Google Scholar 

  29. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth. 2002;49(suppl):Sll–S25.

    Google Scholar 

  30. Schroeder WS, Gandhi PJ. Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, Clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents. Curr Cardiol Rep. 2003;5:310–317.

    Article  PubMed  Google Scholar 

  31. Li YF, Spencer FA, Becker RC. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition. Am Heart J. 2002;143:725–732.

    Article  CAS  PubMed  Google Scholar 

  32. Rocca B, Fitzgerald G A. Simple read: erythrocytes modulate platelet function. Should we rethink the way we give aspirin? Circulation. 1997;95:11–13.

    CAS  PubMed  Google Scholar 

  33. Cutlip DE, Bairn DS, Ho KKL, et al. Stent thrombosis in the modern era. A pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967–1971.

    CAS  PubMed  Google Scholar 

  34. Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era. J Am Coll Cardiol. 2002;40:1567–1572.

    Article  PubMed  Google Scholar 

  35. Reynolds MR, Rinaldi MJ, Pinto DS, et al. Current clinical characteristics and economic impact of subacute stent thrombosis. J Invasive Cardiol. 2002;14:364–368.

    PubMed  Google Scholar 

  36. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)—its relation to metabolic control. Thromb Res. 2004;113:101–113.

    Article  CAS  PubMed  Google Scholar 

  37. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817.

    Article  CAS  PubMed  Google Scholar 

  38. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573–574.

    Article  CAS  PubMed  Google Scholar 

  39. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by non-steroidal antiinflammatory drugs. Circulation. 2003;108:1191–1195.

    Article  CAS  PubMed  Google Scholar 

  40. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol. 2004;43:985–990.

    Article  CAS  PubMed  Google Scholar 

  41. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in health subjects. J Am Coll Cardiol. 2005;45:1295–1301.

    Article  CAS  PubMed  Google Scholar 

  42. Drazen JM. COX-2 inhibitors — a lesson in unexpected problems. N Engl J Med. 2005;352:1131–1132.

    Article  CAS  PubMed  Google Scholar 

  43. Ten Berg JM, Gerritsen WBM, Haas FJLM, et al. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb Res. 2002;105:385–390.

    Article  PubMed  Google Scholar 

  44. Clarke TA, Waskell LA. Clopidogrel is metabolized by human cytochrome P450 3A and inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53–59.

    Article  CAS  PubMed  Google Scholar 

  45. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction.. Circulation. 2003;107:32–37.

    Article  CAS  PubMed  Google Scholar 

  46. Neubauer H, Giinesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function—a flow cytometry study. Eur Heart J. 2003;24:1744–1749.

    Article  CAS  PubMed  Google Scholar 

  47. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166–171.

    Article  CAS  PubMed  Google Scholar 

  48. Saw J, Steinhubl SR, Berger PB, et al., for the Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003;108:921–924.

    Article  CAS  PubMed  Google Scholar 

  49. Cannon CP, Brauwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504.

    Article  CAS  PubMed  Google Scholar 

  50. Müller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation. 2003;108:2195–2197.

    Article  PubMed  Google Scholar 

  51. Steinbuhl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA. 2002;288:2411–2420.

    Article  Google Scholar 

  52. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–2913.

    Article  PubMed  Google Scholar 

  53. Lepantalo A, Virtanen KS, Heikkilä J, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J. 2004;25:476–483.

    Article  CAS  PubMed  Google Scholar 

  54. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol. 2004;16:169–174.

    PubMed  Google Scholar 

  55. Karvouni E, Datritsis DG, Ioannidis JPA. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41:26–32.

    Article  CAS  PubMed  Google Scholar 

  56. Lincoff MA. Important triad in cardiovascular medicine. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation. 2003;107:1556–1559.

    Article  PubMed  Google Scholar 

  57. Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol. 2004;43:8–14.

    Article  PubMed  Google Scholar 

  58. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922–928.

    Article  CAS  PubMed  Google Scholar 

  59. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767–2771.

    Article  CAS  PubMed  Google Scholar 

  60. Vakili BA, Kaplan RC, Slater JN, et al. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention. Am J Cardiol. 2003;91:946–950.

    Article  CAS  PubMed  Google Scholar 

  61. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors. Recognition of a two-edged sword? Circulation. 2002;106:379–385.

    Article  CAS  PubMed  Google Scholar 

  62. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107;1123–1128.

    Article  CAS  PubMed  Google Scholar 

  63. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced isk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (Au-Assessing Ultegra) multicenter study. Circulation. 2001;103:2572–2578.

    CAS  PubMed  Google Scholar 

  64. Soffer D, Moussa I, Karatepe M, et al. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol. 2003;91:872–875.

    Article  CAS  PubMed  Google Scholar 

  65. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol. 2000;36:75–83.

    Article  CAS  PubMed  Google Scholar 

  66. Greinacher A, Eichler P, Lubenow N, et al. Drug-induced and drug-dependent immune thrombocytopenias. Rev Clin Exp Hematol. 2001;5:166–200.

    Article  CAS  PubMed  Google Scholar 

  67. Holmes MB, Kabbani S, Watkins MW, et al. Abciximab-associated pseudothrombocytopenia. Circulation. 2000;101:938–939.

    CAS  PubMed  Google Scholar 

  68. Paradiso-Hardy FL, Madan M, Radhakrishnan S, et al. Severe thrombocytopenia possibly related to readministration of eptifibatide. Catheter Cardiovasc Intervent. 2001;54:63–67.

    Article  CAS  Google Scholar 

  69. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002;100:2071–2076.

    CAS  PubMed  Google Scholar 

  70. Topol EJ, Moliterno DJ, Herrmann HC, et al., for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888–1894.

    Article  CAS  PubMed  Google Scholar 

  71. Fahdi IE, Saucedo JF, Hennebry T, et al. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004;93:453–455.

    Article  CAS  PubMed  Google Scholar 

  72. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies. An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation. 2003;107:2307–2312.

    Article  PubMed  Google Scholar 

  73. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286–1292.

    Article  CAS  PubMed  Google Scholar 

  74. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol. 2003;121:786–792.

    Article  CAS  PubMed  Google Scholar 

  75. Hirsch J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164:361–369.

    Article  Google Scholar 

  76. Sakai K, Oda H, Honsako A, et al. Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy. Catheter Cardiovasc Intervent. 2003;59:351–354.

    Article  Google Scholar 

  77. The Direct Thrombin Inhibitor Trialists’ Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on indi vidual patients’ data. Lancet. 2002;359:294–302.

    Article  Google Scholar 

  78. Mahaffey KW, Lewis BE, Wildermann MN, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15:611–616.

    PubMed  Google Scholar 

  79. Cox CD, Tsikouris JP. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol. 2004;44:327–337.

    Article  PubMed  Google Scholar 

  80. Levine GN, Kern MJ, Berger PB, et al. Management of patients undergoing percutaneous coronary revascularizations. Ann Intern Med. 2003;139:123–136.

    PubMed  Google Scholar 

  81. Gerlach AT, Pickworth KK. Contrast medium-induced nephrotoxicity: pathophysiology and prevention. Pharmacotherapy. 2000;20:540–548.

    Article  CAS  PubMed  Google Scholar 

  82. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldapam mesylate for prevention of contrast-induced nephropathy. JAMA. 2003;290:2284–2291.

    Article  CAS  PubMed  Google Scholar 

  83. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate. JAMA. 2004;291:2328–2334.

    Article  CAS  PubMed  Google Scholar 

  84. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105:656–662.

    Article  PubMed  Google Scholar 

  85. Gibson CM. Has my patient achieved adequate myocardial perfusion? Circulation. 2003;108:504–507.

    Article  PubMed  Google Scholar 

  86. Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol. 2001;37:1335–1343.

    Article  CAS  PubMed  Google Scholar 

  87. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intra-coronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154–2159.

    CAS  PubMed  Google Scholar 

  88. Fugit MD, Rubal BJ, Donovan DJ, et al. Effects of intra-coronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol. 2000;12:80–85.

    CAS  PubMed  Google Scholar 

  89. Dillon WC, Hadian D, Ritchie ME. Refractory no-reflow successfully treated with local infusion of high-dose adenosine and verapamil—a case report. Angiology. 2001;52:137–141.

    Article  CAS  PubMed  Google Scholar 

  90. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Catheter Cardiovasc Diagn. 1996;39:113–118.

    Article  CAS  Google Scholar 

  91. Gregorini L, Marco J, Farah B, et al. Effects of selective alpha-1 and alpha-2 adrenergic blockade on coronary flow reserve after coronary stenting. Circulation. 2002;106:2901–2907.

    Article  CAS  PubMed  Google Scholar 

  92. Tsubokawa A, Ueda K, Sakamoto H, et al. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circulation. 2002;66:119–123.

    Google Scholar 

  93. Gross JB, et al. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002;96:1004–1017.

    Article  Google Scholar 

  94. Martin ML, Lennox PH. Sedation and analgesia in the interventional radiology department. J Vasc Interv Radiol. 2003;14:1119–1128.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice and Science, College of Pharmacy and Senior Clinical Scientist, University of Arizona Sarver Heart Center, Tucson, AZ, 85721, USA

    Paul E. Nolan Jr. PharmD, FCCP, FASHP (Professor)

  2. Department of Pharmacy, Boston Medical Center, Boston, MA, 02118, USA

    Toby C. Trujillo PharmD, BCPS (Clinical Coordinator—Cardiovascular Specialist, Director, Pharmacy Residency Programs)

Authors
  1. Paul E. Nolan Jr. PharmD, FCCP, FASHP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toby C. Trujillo PharmD, BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Cardiology, University of Arizona Sarver Heart Center, Tucson, AZ, 85724, USA

    Samuel M. Butman MD, FACC, FSCAI (Associate Professor of Medicine) (Associate Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Nolan, P.E., Trujillo, T.C. (2005). Complications of the Medications. In: Butman, S.M. (eds) Complications of Percutaneous Coronary Interventions. Springer, New York, NY. https://doi.org/10.1007/978-0-387-29301-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-29301-1_2

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24468-6

  • Online ISBN: 978-0-387-29301-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation